Duktalni karcinom in situ kot predstavnik neinvazivnega raka dojke

Rak dojk je najpogostejši rak pri ženskah. Povprečna starostno standardizirana incidenca (glede na svetovno stardardno populacijo) je v letu 2008 v Evropski skupnosti znašala 70,7. Leta 2003 je Evropska skupnost izdala direktivo o izvajanju presejalnih programov po načelih dobre prakse. Prednost presejalnega programa je, da se rak odkrije v zgodnjejši fazi, ko so možnosti zdravljenja in ozdravitve večje. S presejalno mamografijo se je močno povečala incidenca neinvazivnih rakov, kot je duktalni karcinom in situ (DCIS). Tako v nekaterih državah DCIS predstavlja že 20-30 % raka dojk. Glavni cilj zdravljenja DCIS je prevencija nastanka invazivnega raka dojk. Zdravljenje je kirurško in obsevalno. Smiselno bi bilo DCIS beležiti ločeno od invazivnih rakov, z oznako, ki ne bi vsebovala besede karcinom.

• Publication year

  2022

• Venue

  Pomurska obzorja

• Publication date

  2022-04-12

• Fields of study

  Not labeled

• Identifiers
  DOI 10.18690/pomurska-obzorja.2.3.27-29.2015
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Ductal Carcinoma in Situ of the Breast

  2018cited by this paper
• Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.

  2014cited by this paper
• Breast cancer in European Union: An update of screening programmes as of March 2014 (Review)

  2014cited by this paper
• Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?

  2013cited by this paper
• Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer.

  2012cited by this paper
• Review: Statistical Models: Theory and Practice (Revised Edition). Cambridge University Press, New York, New York, 2009, xiv + 442 pp., ISBN 978-0-521-74385-3, $40. by David A. Freedman

  2010cited by this paper
• Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

  2010cited by this paper
• Screening caused rising incidence rates of ductal carcinoma in situ of the breast

  2009cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Radiation-induced malignancies following radiotherapy for breast cancer

  2004cited by this paper
• IARC Handbooks of Cancer prevention

  2003cited by this paper
• IARC Handbooks of Cancer Prevention, Volume 7: Breast Cancer Screening

  2003cited by this paper
• Histological and biological evolution of human premalignant breast disease.

  2001cited by this paper
• Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.

  1999cited by this paper
• Predictors of local recurrence after treatment of ductal carcinoma in situ - A meta-analysis

  1999cited by this paper
• Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy

  1995cited by this paper

• No citing papers are available for this paper.